

R H I N O M E D

18 December 2023

Rhinomed Limited (ASX:Rhinomed) - Cleansing notice in respect of share purchase plan

This notice is given by Rhinomed Limited ACN 107 903 159 (ASX: RNO) (**Rhinomed**).

1. Background

On 11 December 2023, Rhinomed announced its intention to offer eligible shareholders the opportunity to subscribe for new fully paid ordinary shares in Rhinomed (**New Shares**) under a share purchase plan (**SPP**).

Rhinomed relies on *ASIC Corporations (Share and Interest Purchase Plan) Instrument 2019/547 (ASIC Instrument)* in relation to the issue of the New Shares under the SPP.

2. Cleansing notice in respect of the New Shares issued under the SPP

With respect to the SPP, Rhinomed advises that:

- (a) the New Shares will be offered without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (**Corporations Act**);
- (b) this notice is being given in accordance with the ASIC Instrument;
- (c) as at the date of this notice, Rhinomed has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to RNO; and
 - (ii) section 674 of the Corporations Act as it applies to RNO;
- (d) as at the date of this notice, there is no excluded information to be provided in accordance with subsections 708A(7) and 708A(8) of the Corporations Act as if this notice were a notice under subsection 708A(5)(e) of the Corporations Act.

This notice is dated 18 December 2023 and is given to ASX Limited within the 24 hour period before the offer under the SPP is made by Rhinomed. A copy of the SPP offer documents for shareholders of Rhinomed will be separately lodged with ASX today.

This notice has been authorised for ASX release by the Rhinomed Board of Directors.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.